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Background-—Acute kidney injury (AKI) is a major risk factor for the development of chronic kidney disease. Nuclear factor-jB is a
nuclear transcription factor activated post-ischemia, responsible for the transcription of proinflammatory proteins. The role of
nuclear factor-jB in the renal fibrosis post-AKI is unknown.
Methods and Results-—We used a rat model of AKI caused by unilateral nephrectomy plus contralateral ischemia (30 minutes) and
reperfusion injury (up to 28 days) to show impairment of renal function (peak: 24 hours), activation of nuclear factor-jB (peak:
48 hours), and fibrosis (28 days). In humans, AKI is diagnosed by a rise in serum creatinine. We have discovered that the IjB
kinase inhibitor IKK16 (even when given at peak serum creatinine) still improved functional and structural recovery and reduced
myofibroblast formation, macrophage infiltration, transforming growth factor-b expression, and Smad2/3 phosphorylation. AKI
resulted in fibrosis within 28 days (Sirius red staining, expression of fibronectin), which was abolished by IKK16. To confirm the
efficacy of IKK16 in a more severe model of fibrosis, animals were subject to 14 days of unilateral ureteral obstruction, resulting in
tubulointerstitial fibrosis, myofibroblast formation, and macrophage infiltration, all of which were attenuated by IKK16.
Conclusions-—Inhibition of IjB kinase at peak creatinine improves functional recovery, reduces further injury, and prevents
fibrosis. ( J Am Heart Assoc. 2017;6:e005092. DOI: 10.1161/JAHA.116.005092.)
Key Words: acute kidney injury • fibrosis • ischemia • IjB kinase
I t is now widely recognized that acute kidney injury (AKI) isa major risk factor for chronic kidney disease (CKD), even
in patients who regain full renal function post-AKI.1 Patients
with severe AKI (especially dialysis-requiring AKI) have a
higher probability of developing CKD than those with less
severe AKI2 and an increased risk of cardiovascular mortality
and proteinuria.3 Up to 8% of hospitalized patients present
with AKI, of which 60% will never regain full renal function.4
Progression of AKI to CKD occurs in both patients1 and
animal5,6 models of AKI. After AKI, prolonged inflammation
and maladaptive or incomplete regenerative processes
encourage fibrosis and ultimately CKD.7 In patients, AKI is
diagnosed by a rise in creatinine, which occurs 24 to 72 hours
after AKI. In animals, interventions aimed at reducing AKI are
frequently given either before or immediately after AKI, which
limits the translation of these findings to cases of AKI
associated with transplantation and coronary artery bypass
graft surgery.8 This study was designed to develop an
intervention that can be given after AKI at a time point when
a significant rise in creatinine has occurred, which is able to
improve recovery and prevent the development of fibrosis.
Nuclear factor-jB (NF-jB) is a nuclear transcription factor
activated by cytokines and chemokines after AKI, resulting in
the transcription of various inflammatory mediators.9,10
Activation of NF-jB is dependent on the activation of IjB
kinase (IKK), a 3-subunit protein (comprising a, b, and c
subunits). AKI causes activation of IKKb,11 resulting in
formation of an activated IKK complex with IKKa and IKKc,
causing IjBa phosphorylation (at Ser32/36) and consequently
From the Barts and The London School of Medicine & Dentistry, The William
Harvey Research Institute, Queen Mary University of London, United Kingdom
(F.L.J., N.S.A.P., G.S.D.P., J.C., R.S., G.H., V.V.M., M.M.Y., C.T.); Department of
Drug Science and Technology, University of Turin, Italy (F.C., M.C.); Department
of Molecular Biology and Genetics, Universidade Estadual de Ponta Grossa,
Ponta Grossa, Parana, Brazil (R.S.); Aix Marseille Universite, UMR_S 1076,
Vascular Research Center of Marseille, France (G.H.).
Accompanying Table S1 and Figure S1 are available at http://jaha.ahajourna
ls.org/content/6/7/e005092/DC1/embed/inline-supplementary-material-
1.pdf
*Dr Johnson and Dr Patel contributed equally to this work.
Correspondence to: Christoph Thiemermann, MD, PhD, Barts and The
London School of Medicine & Dentistry, William Harvey Research Institute,
Queen Mary University of London, Charterhouse Square, London EC1M 6BQ,
United Kingdom. E-mail: c.thiemermann@qmul.ac.uk
Received November 19, 2016; accepted March 22, 2017.
ª 2017 The Authors. Published on behalf of the American Heart Association,
Inc., by Wiley. This is an open access article under the terms of the Creative
Commons Attribution-NonCommercial License, which permits use, distribu-
tion and reproduction in any medium, provided the original work is properly
cited and is not used for commercial purposes.
DOI: 10.1161/JAHA.116.005092 Journal of the American Heart Association 1
ORIGINAL RESEARCH
 by guest on January 14, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
nuclear translocation of NF-jB and gene transcription.12
Pretreatment of animals with small interfering RNA against
IKKb 48 hours prior to renal ischemia reperfusion injury (IRI)
has been shown to reduce renal dysfunction and injury.11
Mice expressing the human NF-jB superrepressor IjBaDN in
renal proximal, distal, and collecting duct epithelial cells have
shown improved renal function and attenuated inflammatory
cells infiltration after renal IRI.13
Compound IKK16 [N-(4-Pyrrolidin-1-yl-piperidin-1-yl-)-[4-(4-
benzo [b]thiophen-2-yl-pyrimidin-2-ylamino)-phenyl] carbox-
amide hydrochloride] is a selective inhibitor of IKK. IKK16
targets the IKK inhibitor motifs (2-anilino-pyrimidines and 2,4-
disubstituted quinazolines). IKK16 is a potent IKK inhibitor in
the low nanomolar range, with IC50 values of 40, 70, and
200 nmol/L for IKKb, IKK complex, and IKKa inhibition,
respectively.14
In this study, we report that administration of IKK16 at
24 hours after AKI (ie, when the peak in the rise in creatinine
had already occurred) improves functional recovery (at
48 hours) and attenuates fibrosis at 28 days after AKI.
Methods
The animal protocols followed in this study were approved by
the local Animal Use and Care Committee in accordance with
the derivatives of both the Home Office Guidance on the
Operation of Animals (Scientific Procedures) Act 1986
published by Her Majesty’s Stationary Office and the Guide
for the Care and Use of Laboratory Animals of the National
Research Council.
Acute Kidney Injury
Surgical procedure and quantification of organ injury/
dysfunction
This study was carried out on 74 male Wistar rats (Charles
River Ltd, Margate, UK) weighing between 240 and 290 g
and receiving a standard diet and water ad libitum. Animals
were anesthetized using a ketamine (150 mg/kg) and
xylazine (15 mg/kg) mixture IP (1.5 mL/kg). The hair was
shaved and the skin cleaned with 70% alcohol (v/v). The
animals were then placed on a homeothermic blanket set
at 37°C. Animals received 0.1 mg/kg SC buprenorphine
(0.1 mL/kg) prior to commencement of surgery. A midline
laparotomy was then performed. The right renal pedicle
(consisting of the renal artery, vein, and nerve) was isolated
and tied off using a sterile 4-0 silk-braided suture (Pearsalls
Ltd, Taunton, UK). The right kidney was then surgically
removed. The left renal pedicle was isolated and clamped
using a nontraumatic microvascular clamp at time 0. After
30 minutes of unilateral renal ischemia, the clamp was
removed to allow reperfusion. For reperfusion, the kidneys
were observed for a further 5 minutes to ensure reflow,
following which 8 mL/kg saline at 37°C was injected into
the abdomen and all incisions were sutured in 2 layers
(Ethicon Prolene 4-0). Animals were then allowed to recover
on the homeothermic blanket and placed into cages upon
recovery. Twenty-four hours prior to the end of the
experiment, the rats were placed in metabolic cages for
the collection of urine and the subsequent determination of
both estimated creatinine clearance and fractional excretion
of sodium. At the end of the experiment, blood was taken
by cardiac puncture into nonheparinized syringes and
immediately decanted into 1.3-mL serum gel tubes (Sarst-
edt, Germany). The blood was centrifuged at 9900g for
5 minutes to separate serum. All biochemical markers in
serum and urine were measured in a blinded fashion by a
commercial veterinary testing laboratory (IDEXX Ltd, West
Sussex, UK). The left kidney was removed following removal
of the heart. Half of the left kidney was snap-frozen and
stored at 80°C, and the other half was stored in 10%
neutral buffered formalin.
Experimental design (acute time course)
Rats were randomly allocated into the following groups: (1)
pre-ischemia (n=4); (2) 24 hours reperfusion (n=4); (3)
48 hours reperfusion (n=8); and (4) 72 hours reperfusion
(n=4).
Experimental design (late intervention)
Rats were randomly allocated into the following groups: (1)
sham+vehicle (n=11); (2) IRI+vehicle (n=11); (3) IRI+IKK16
0.1 mg/kg (n=5); (4) IRI+IKK16 0.3 mg/kg (n=7); and (5)
IRI+IKK16 1 mg/kg (n=9). Rats were administered vehicle
(10% dimethyl sulfoxide) or N-(4-Pyrrolidin-1-yl-piperidin-1-yl)-
[4-(4-benzo[b]thiophen-2-yl-pyrimidin-2-ylamino)phenyl] car-
boxamide hydrochloride (IKK16) (a specific inhibitor of IKK)
24 hours after the onset of reperfusion via the tail vein at a
volume of 1 mL/kg. IKK16 was purchased from Tocris
Bioscience (R&D systems Europe, Abingdon, UK), and the
optimal dose obtained from previous IC50 values
14 and a dose
response (data not shown).
Experimental design (28 day time course and late
intervention)
Rats were randomly allocated into the following groups: (1)
sham+vehicle: n=8; (2) 1 day postreperfusion: n=4; (3)
2 days postreperfusion: n=4; (4) 7 days postreperfusion:
n=4; (5) 14 days postreperfusion: n=4; (6) 28 days postreper-
fusion: n=7; (7) 1 mg/kg IKK16 24 hours postreperfu-
sion+7 day reperfusion: n=7; and (8) 1 mg/kg IKK16
24 hours postreperfusion+28 day reperfusion: n=7. Rats
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were administered vehicle (10% dimethyl sulfoxide) or IKK16
24 hours after the onset of reperfusion via the tail vein at a
volume of 1 mL/kg.
Unilateral Ureteral Obstruction
Surgical procedure and quantification of organ injury/
dysfunction
This study was carried out on 25 male Wistar rats (Charles
River Ltd, Margate, UK) weighing between 240 and 290 g and
receiving a standard diet and water ad libitum. Animals were
anesthetized using a ketamine (150 mg/kg) and xylazine
(15 mg/kg) mixture intraperitoneally (1.5 mL/kg). The hair
was shaved and the skin cleaned with 70% alcohol (v/v). The
animals were then placed on a homoeothermic blanket set at
37°C. Animals received 0.1 mg/kg SC buprenorphine
(0.1 mL/kg) prior to commencement of surgery. A midline
laparotomy was then performed. The right renal ureter was
isolated and tied off 0.5 cm from the renal pelvis using a
sterile 5-0 silk-braided suture (Pearsalls Ltd, Taunton, UK)
following which 8 mL/kg saline at 37°C was injected into the
abdomen and all incisions were sutured in 2 layers (Ethicon
Prolene 5-0). Animals were then allowed to recover on the
homeothermic blanket and placed into cages upon recovery.
At the end of the experiment, both kidneys were removed
following removal of the heart and was stored in 10% neutral
buffered formalin. The nonligated ureteral kidney served as
sham.
Experimental design (late intervention)
The rats were randomly allocated into the following groups:
(1) contralateral sham (n=11) (contralateral kidneys belonging
to groups 2 and 3); (2) unilateral ureteral obstruction
(UUO)+vehicle (n=9); and (3) UUO+IKK16 1 mg/kg (n=10).
Rats were administered vehicle (10% dimethyl sulfoxide) or
IKK16 through days 7 to 13 post-ureteral obstruction
subcutaneously at a volume of 1 mL/kg.
Histological Evaluation
The kidneys were fixed in 10% neutral buffered formalin for
48 hours before being dehydrated with 70% ethanol.
Tissues were embedded in paraffin and sections were cut
at 4 lm by a single technician in order to minimize
variations in section thickness. The slides were deparaf-
finized with xylene, stained with hematoxylin and eosin, and
viewed with a NanoZoomer Digital Pathology Scanner
(Hamamatsu Photonics K.K., Japan). Ten random images
were taken per slide and quantified for tubular dilatation by
determining percentage background white space using
ImageJ as a marker of renal injury.
Histochemical Sirius Red Staining
Sections were deparaffinized and rehydrated through graded
alcohols to distilled water. Sections were treated with
phosphomolybdic acid (Polysciences, Warrington, PA), rinsed
in distilled water, and stained with picrosirius red (Poly-
sciences) for 60 minutes at room temperature. Sections were
then immediately immersed in hydrochloride acid for 2 min-
utes before being dehydrated through graded alcohols and
cleared. Ten images per section were taken with the
NanoZoomer Digital Pathology Scanner, and quantification
of Sirius red was performed using ImageJ analysis software
(National Institutes of Health, Bethesda, MD).
Immunohistochemistry
Sections cut at 4 lm were dewaxed and deparaffinized to
PBS. Antigen retrieval was performed by microwaving (700 W)
sections in citrate buffer (pH 6.0) for 15 minutes. Once
cooled, sections were incubated with 3% H2O2 for 20 minutes
to inactivate endogenous peroxidises (Dako EnVision+ Sys-
tem-HRP-DAB, K4010) and subsequently treated with 10%
normal goat serum (Dako, UK) to reduce nonspecific absorp-
tion. Sections were subsequently incubated at 37°C for
1 hour with the following primary antibodies: anti-a-smooth
muscle actin antibody (1:400, cat#ab5694, Abcam, UK) or
anti-CD68 antibody ED1 (1:400; cat#MCA341R, AbD Serotec,
UK), washed with PBS, and then incubated at room temper-
ature for 30 minutes with labelled polymer-HRP antibody
(Dako EnVision+ System, HRP-DAB). Sections were developed
in DAB chromogen solution, and the reaction stopped by
immersion of sections in water. Counterstaining was per-
formed with Harris hematoxylin before sections were dehy-
drated and mounted in DPX mounting medium. Ten images
per section were acquired with the NanoZoomer Digital
Pathology Scanner in a double-blinded manner. Quantification
of staining was then performed using ImageJ analysis
software.
Immunofluorescence
Sections cut at 4 lm were dewaxed and deparaffinized to
PBS. Antigen retrieval was performed by microwaving (700 W)
sections in citrate buffer (pH 6.0) for 15 minutes. Once
cooled, sections were incubated with 3% H2O2 for 20 minutes
to inactivate endogenous peroxidises (Dako EnVision+ Sys-
tem, HRP-DAB, K4010), and subsequently treated with 10%
bovine serum albumin (Dako, UK). Sections were subse-
quently incubated at 4°C for 18 hours with the primary
antibodies anti-p65 (1:400, Cell Signaling, UK), washed with
PBS, and then incubated at room temperature for 1 hour with
a secondary antibody with preconjugated Alexa Fluor goat
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anti-rabbit (Life Technologies, UK), washed with PBS, and
mounted in DAPI containing mounting medium. Stained
sections were visualized using Leica DM5500 B (Leica
Microsystems, UK).
Western Blot Analysis
Western blots were carried out as previously described.15,16
Three separate experiments of Western blot analysis were
performed for each marker and tissues were done separately
for each Western blot experiment. Briefly, previously snap-
frozen rat kidney samples were homogenized and centrifuged
at 4000g for 5 minutes at 4°C. Supernatants were removed
and centrifuged at 15 000g at 4°C for 40 minutes to obtain
the cytosolic fraction. The pelleted nuclei were resuspended
in extraction buffer. The suspensions were centrifuged at
15 000g for 20 minutes at 4°C. The resulting supernatants
containing nuclear proteins were carefully removed, and
protein content was determined using a bicinchoninic acid
protein assay following the manufacturer’s directions. Pro-
teins were separated by 8% SDS-PAGE and transferred to a
polyvinylidene fluoride membrane, which was then incubated
with a primary antibody mouse anti-total IjBa (1:1000
cat#ab7217, Abcam, UK); mouse anti-pIjBa Ser32/36
(1:1000 cat#ab12135, Abcam, UK); rabbit anti-NF-jB p65
(1:1000 cat#ab16502, Abcam, UK); rabbit anti–transforming
growth factor-b (TGF-b) (1:1000, cat#ab66043); rabbit anti-
fibronectin (1:1000, cat#ab2413, Abcam, UK); rabbit anti-
pSmad2 Ser465/467/Smad3 Ser423/425 (1:1000, cat#D27F4,
Cell Signaling Technologies, MA); and rabbit anti-Smad2/3
(1:1000, cat#D7G7, Cell Signaling Technologies, MA). Blots
were then incubated with a secondary antibody conjugated
with horseradish peroxidase (dilution 1:10 000) and devel-
oped using an enhanced chemiluminescence detection sys-
tem. The immunoreactive bands were visualized by
autoradiography. The membranes were stripped and incu-
bated with b-actin monoclonal antibody (1:5000) or rabbit
GAPDH antibody (1:1000, cat#D16H11, Cell Signaling Tech-
nologies, MA) and subsequently with an anti-mouse antibody
(1:10 000 cat#7076, Cell Signaling Technologies, MA) to
assess gel-loading homogeneity. Densitometric analysis of the
bands was performed using Gel ProAnalyzer 4.5, 2000
software (Media Cybernetics, Silver Spring, MD) and optical
density analysis was expressed as a fold-increase versus the
sham group. In the sham group, the immunoreactive bands of
the gel were respectively measured and normalized against
the first immunoreactive band (standard sham sample) and
the results of all the bands belonging to the same group were
expressed as meanSEM. This provides SEM for the sham
group where a value of 1 is relative to the first immunore-
active band. Relative band intensity was assessed and
normalized against parallel b-actin expression.
Materials
Unless otherwise stated, all compounds used in this study
were purchased from Sigma-Aldrich Company Ltd (Poole,
Dorset, UK).
Statistical Analysis
All values described in the text and figures are expressed as
meanSEM for the number of observations. Each data point
represents biochemical measurements obtained from up to
11 separate animals. Statistical analysis was carried out using
GraphPad Prism 6.0b (GraphPad Software, San Diego, CA).
Data without repeated measurements were assessed by
1-way ANOVA followed by Bonferroni’s multiple-comparison
post-hoc test. The area under the curve was calculated by
plotting the values of serum creatinine at days 1, 2, 7, 14, 21,
and 28 postreperfusion. Linear regressions were calculated by
the least squares method and their significance were
estimated by Fisher F test. A P value <0.05 was considered
to be significant.
Results
Effect of Inhibition of IjB Kinase on Renal,
Glomerular, and Tubular Function
When compared with baseline (pre-ischemia), rats with IRI/
24 hours reperfusion developed significant renal (rises in
serum urea and serum creatinine [SCr]) (both P<0.0001,
Figure 1A and 1B), glomerular (fall in estimated creatinine
clearance [eCCL]) (P<0.0001, Figure 1C), and tubular dys-
function (rise in fractional excretion of sodium) (P<0.0001,
Figure 1D), along with increases in kidney injury molecule-1
(P<0.05, Figure S1), followed by progressive recovery of renal,
glomerular, and tubular function without intervention (Fig-
ure 1). When compared with sham-operated rats, rats with
IRI/48 hours reperfusion showed increases in serum urea
(P<0.0001, Figure 1A), SCr (P<0.0001, Figure 1B), and kidney
injury molecule-1 (P<0.05, Figure S1), and a significant
decrease in eCCL (P<0.001, Figure 1C), indicating the
development of AKI. Having discovered that the peak renal
dysfunction following 30 minutes of unilateral renal ischemia
occurs at 24 hours of reperfusion and that maximal renal
injury (Figure 2) and activation of IKK (Figure 3) occur
between 24 and 48 hours of reperfusion, IKK16 was admin-
istered at 24 hours after the onset of reperfusion. Compared
with rats subjected to IRI only, treatment of rats with IKK16
(1 mg/kg) at 24 hours into reperfusion resulted in a signif-
icant and substantial attenuation of serum urea (P<0.0001,
Figure 1A), SCr (P<0.0001, Figure 1B), and eCCL (P<0.0001,
Figure 1C) at 48 hours postreperfusion, while lower doses of
IKK16 had no significant effect (Table S1).
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When compared with sham-vehicle, rats that underwent
IRI/48 hours reperfusion developed tubular dilatation
(P<0.0001, Figure 2C and 2F), a hallmark of AKI pathol-
ogy,17,18 as did rats subjected to IRI/72 hours reperfusion
(P<0.0004, Figure 2D). The administration of IKK16 at peak
creatinine (1 mg/kg; at 24 hours after the onset of reperfu-
sion) significantly reduced signs of histological injury when
compared with control-vehicle rats subjected to IRI/48 hours
(P<0.0007, Figure 2E and 2F).
Kidneys from rats with IRI/48 hours reperfusion exhib-
ited significant phosphorylation of Ser32/36 on IjBa
(P=0.0033, Figure 3A) and, hence, phosphorylation
(Ser176/180 of IKKa/b) and activation of the IKK complex
(P=0.0075, Figure 3B), as well as nuclear translocation of
the NF-jB subunit p65 (P<0.0001, Figure 3C). Interestingly,
administration of IKK16 significantly attenuated the
increase in the phosphorylation of IjBa on Ser32/36
(P=0.0154, Figure 3D), phosphorylation (Ser176/180 of
IKKa/b) and activation of IKK (P=0.0006, Figure 3E), and
the subsequent nuclear translocation of the p65 NF-jB
subunit (P<0.0001, Figure 3F and 3G) caused by unilateral
IRI. Thus, IKK16 attenuated the activation of NF-jB that
occurred between 24 and 48 hours of reperfusion.
IjB Kinase Inhibition Inhibits Fibrosis (Day 28)
At 28 days postreperfusion, animals treated with either
vehicle or IKK16 showed no renal dysfunction (rise in SCr,
Figure 1. The effect of 30 minutes ischemia followed by different lengths of reperfusion (24, 48, or
72 hours) on glomerular and tubular function, and the effect of late administration of the IjB kinase
inhibitor IKK16 (at 24 hours into reperfusion, followed by 48 hours of reperfusion). Serum urea (A), serum
creatinine (B), and estimated creatinine clearance (C) were measured as indicators of glomerular function,
and fractional excretion of sodium (D) as an indicator of tubular function (in different sets of animals for
each time point). The peak of dysfunction occurs 24 hours after the onset of reperfusion. Sham+vehicle
(10% dimethyl sulfoxide): n=4; ischemia reperfusion injury (IRI)+24 hours: n=4; IRI+48 hours (+vehicle):
n=8; IRI+72 hours (+vehicle): n=4; and IRI+48 hours, IKK16 1 mg/kg (1 mL/kg IV) 24 hours into
reperfusion (culled at 48 hours postreperfusion): n=9. Data are presented as meanSEM for the number of
observations. *P<0.05 vs sham+vehicle unless otherwise stated.
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P=0.4520 [Figure 4A] or kidney injury molecule-1, P=0.11
[Figure S1]) when compared with sham-operated rats.
Kidneys from rats with IRI/28 day reperfusion exhibited
significant increases in Sirius red staining and, hence,
fibrosis (P=0.0396, Figure 4B and 4C). IKK16 significantly
attenuated the increase in Sirius red staining for collagen I
and III and, therefore, fibrosis (P=0.0264, Figure 4B and
4C). Regression analysis revealed a significant linear
relationship between renal dysfunction and fibrosis, Sirius
red staining at day 28 versus SCr on day 2 (P=0.0008,
Figure 5A), Sirius red staining at day 28 versus eCCL on
day 2 (P=0.0002, Figure 5B), and Sirius red staining at
28 days versus area under the curve of SCr from days 1 to
28 (P=0.0006, Figure 5C), indicating that the degree of
renal dysfunction on day 2 predicts the severity of fibrosis
on day 28.
A B
C D
E F
Figure 2. The effect of 30 minutes ischemia followed by different lengths of reperfusion (24, 48, or
72 hours) on renal injury, and the effect of late administration of the IjB kinase inhibitor IKK16 24 hours
into reperfusion. Representative histological hematoxylin-eosin images (scale bar, 100 lm) of rat renal
tissue were taken from groups without renal ischemia (sham+vehicle) (A) or from rats subjected to
30 minutes of renal ischemia followed by reperfusion for 24 hours (B), 48 hours (+vehicle) (C), and
72 hours (+vehicle) (D), and after 48 hours of reperfusion with treatment of IKK16 (1 mg/kg IV) 24 hours
into reperfusion (E). Ten randomly selected fields from 3 individual kidneys (n=3) per group were selected
and analyzed (total fields=30) for the determination of percentage background white space using ImageJ
software, representing tubular dilatation (F). Data are presented as meanSEM for the number of
observations. *P<0.05 vs pre-ischemia.
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Figure 3. The effect of 30 minutes ischemia followed by different lengths of reperfusion (24, 48, or 72 hours) and
the effect of late administration on the nuclear factor jB (NF-jB) pathway. Activation of IjBa was measured as
phosphorylation of Ser32/36 on IjBaduring the course of reperfusion (A) andwith the administration of the IjB kinase
inhibitor IKK16 at 24 hours postreperfusion (D). The activation of IjBa results in the activation of IKK, measured as
the phosphorylation of IKKa/b at Ser176/180 during the course of reperfusion (B) andwith the administration of IKK16
at 24 hours postreperfusion (E). Activation of IKK results in nuclear translocation of the p65 subunit of NF-jB (shown
in C and G) and the effect on the nuclear translocation of the p65 subunit of NF-jB with the administration of IKK16
24 hours postreperfusion (F andG). (Representative imagesdisplayed inG), p65 images960magnification (scale bar
100 lm) and zoom960 magnification plus92.5 digital zoom (scale bar 40 lm). (A, B, and C) Sham+vehicle: n=4;
ischemia reperfusion injury (IRI)+24 hours: n=4; IRI+48 hours (+vehicle): n=4; and IRI+72 hours (+vehicle): n=4. (C,
D, and E) Sham+vehicle: n=4; IRI+vehicle: n=5; and IRI+IKK16 1 mg/kg: n=5. Data are presented asmeanSEM for
the number of observations. P<0.05 vs sham (A+B+C), *P<0.05 vs IRI+vehicle (D+E+F). OD indicates optical density.
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Effect of IKK16 on a-Smooth Muscle Actin and
CD68+ Staining, Transforming Growth Factor-b,
and Smad2/3 Phosphorylation (Ischemia
Reperfusion Injury/7 Days)
Kidneys from rats with IRI/7 days reperfusion exhibited
significant increases in a-smooth muscle actin staining
(myofibroblast formation, P<0.0001 [Figure 6A and 6C]) and
CD68+ staining (macrophage infiltration, P=0.0001 [Fig-
ure 6B and 6C]), both of which were abolished by IKK16
(Figure 6A and 6C). Kidneys from rats with IRI/7 days
reperfusion also exhibited significant increases in TGF-b
(P=0.0001, Figure 7A) and Smad2/3 phosphorylation
(P<0.0001, Figure 7B), both of which were abolished
by IKK16 (P<0.0001 and P=0.0014, respectively [Figure 7A
and 7B]).
Figure 4. The effect of late administration of the IjB kinase inhibitor IKK16 (24 hours postreperfusion) on the development of fibrosis (as
measured by Sirius red for collagen I and III) after a 28-day reperfusion period. A, Serum creatinine values in sham+vehicle (nephrectomy only,
28 days recovery): n=4; 28 days postreperfusion (control): n=9; and 1 mg/kg IKK16 24 hours postreperfusion+28 day reperfusion: n=8. B, The
time course of development of fibrosis in rats after 30 minutes ischemia followed by different lengths of reperfusion (images for these data
shown in C): top row shows cross section of representative groups (scale bar, 3 mm) and bottom row shows representative images at 980
magnification (scale bar, 250 lm). Sham+vehicle: n=4; 1 day postreperfusion: n=4; 2 days postreperfusion: n=4; 7 days postreperfusion: n=4;
14 days postreperfusion: n=4; 28 days postreperfusion: n=8; and 1 mg/kg IKK16 24 hours postreperfusion+28 day reperfusion: n=7. Due to
the concentration of the fibrosis in the corticomedullary junction, whole tissue cross sections (as seen in the top row of C) were analyzed and
the percentage staining for Sirius red per tissue field calculated by ImageJ software. These values were then normalized to surface area
percentage. Data are presented as meanSEM for the number of observations. *P<0.05 vs sham+vehicle.
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Effect of Late Inhibition of IjB Kinase on
Fibronectin in the Rat Kidney at 28 Days
Postreperfusion
We measured fibronectin (an extracellular matrix component)
at 28 days post-IRI in order to substantiate our histological
finding that a significant degree of fibrosis had occurred at
this time point. Using Western blot analysis, we confirm that
30 minutes of unilateral renal ischemia and 28 days of
reperfusion resulted in a significant increase in the expression
of fibronectin (P<0.0001, Figure 8). Administration of IKK16
prevented the expression of fibronectin (P<0.0001, Figure 8)
caused by unilateral IRI and 28 days of reperfusion.
Effect of Inhibition of IjB Kinase in a Rat Model of
Unilateral Ureteral Obstruction
UUO resulted in tubulointerstitial fibrosis within 14 days as
determined by increased staining for Sirius red (for collagen I
and III) (P<0.0001, Figure 9) and a-smooth muscle actin (for
myofibroblast formation) (P<0.0001, Figure 9). When com-
pared with rats treated with vehicle, rats treated with IKK16
(1 mg/kg SC) on days 7 to 13 following UUO resulted in a
significant reduction in both Sirius red (P<0.0001, Figure 9)
and a-smooth muscle actin staining (P=0.0161, Figure 9) and,
therefore, a reduction in tubulointerstitial fibrosis at day 14,
indicating that activation of the IKK complex drives the
development of tubulointerstitial fibrosis. Furthermore, com-
pared with contralateral kidneys, kidneys of rats that had
been subjected to UUO for 14 days demonstrated a signif-
icant increase in CD68+ staining, indicating macrophage
accumulation (P=0.0007, Figure 9). The treatment of rats with
IKK16 (1 mg/kg SC) on days 7 to 13 following UUO resulted
in a significant reduction in CD68+ staining, and therefore a
reduced macrophage accumulation in the renal tissue
(P=0.0343, Figure 9).
UUO (14 days) was associated with significant phospho-
rylation of Ser32/36 on IjBa (P<0.0001, Figure 10A) and,
Figure 5. Correlation data to show (A) serum creatinine (SCr) at day 2 vs Sirius red percentage per tissue
field (indicative of fibrosis) at day 28, (B) the estimated creatinine clearance at day 2 vs Sirius red
percentage per tissue field (indicative of fibrosis) at day 28, and (C) area under the curve (AUC) of SCr
concentration (from day 1 to day 28) vs Sirius red percentage per tissue field (indicative of fibrosis) at day
28. All animal data (sham+vehicle, ischemia reperfusion injury [IRI]+vehicle, and IRI+IKK16 24 hours
postreperfusion) are included in these graphs. AUC was calculated after plotting the values of SCr at day 1,
2, 7, 14, 21, and 28 postreperfusion. Linear regressions were calculated by the least squares method and
their significance were estimated by Fisher F test. P<0.05 was considered to be significant.
DOI: 10.1161/JAHA.116.005092 Journal of the American Heart Association 9
Delayed IKK16 at Peak Creatinine Protects Kidney Johnson et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on January 14, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
hence, phosphorylation (Ser176/180 of IKKa/b) and activation
of the IKK complex (P<0.0001, Figure 10B), as well as nuclear
translocation of the NF-jB subunit p65 (P<0.0001, Fig-
ure 10C and 10G). Administration of IKK16 on days 7 to 13 of
UUO significantly attenuated the increase in the phosphory-
lation of IjBa on Ser32/36 (P=0.0011, Figure 10A), phospho-
rylation (Ser176/180 of IKKa/b) and activation of IKK
(P<0.0001, Figure 10B), and the subsequent nuclear translo-
cation of the p65 NF-jB subunit (P=0.0006, Figure 10C and
10G) caused by UUO. Moreover, rats subjected to 14 days of
UUO (+vehicle) exhibited a significant increase in TGF-b
(P<0.0001, Figure 10D), phosphorylation of Smad2/3
(P<0.0001, Figure 10E), and fibronectin (P<0.0001, Fig-
ure 10F) in the renal tissue. The inhibition of IKK administered
on days 7 to 13 after UUO attenuated increases in TGF-b
(P<0.0001, Figure 10D), phosphorylation of Smad2/3
(P=0.0001, Figure 10E), and fibronectin (P=0.0021, Fig-
ure 10F) in the renal tissue.
Discussion
There is now good evidence that the severity of AKI correlates
with the progression of AKI to CKD: the more severe and
prolonged the initial ischemic insult, the higher the probability
Figure 6. The effect of the late administration of the IjB kinase inhibitor IKK16 (24 hours postreperfusion) on the expression of a-smooth
muscle actin (a-SMA) for a-SMA–positive myofibroblasts (A) and CD68+ for CD68+-positive myofibroblasts (B) after a 28-day reperfusion period.
(Representative images displayed in C), a-SMA images 980 magnification (scale bar, 250 lm), CD68+ images 9200 magnification (scale bar,
100 lm). Ten randomly selected fields from each kidney were selected and analyzed for the determination of percentage stained rat kidney
tissue using ImageJ software. Sham+vehicle: n=8 (80 total fields), 1 day postreperfusion: n=4 (40 total fields); 2 days postreperfusion: n=4 (40
total fields); 7 days postreperfusion: n=4 (40 total fields); 14 days postreperfusion: n=4 (40 total fields); 28 days postreperfusion: n=7 (70 total
fields); 1 mg/kg IKK16 24 hours postreperfusion+7 day reperfusion: n=7 (70 total fields); and 1 mg/kg IKK16 24 hours postreperfu-
sion+28 day reperfusion: n=7 (70 total fields). Data are presented as meanSEM for the number of observations. *P<0.05 vs sham+vehicle,
unless otherwise stated.
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of developing CKD later in life.2 Thus, the quick amelioration
of the IRI-dependent changes in biochemical markers follow-
ing AKI by new therapies may reduce the probability of
developing CKD. AKI is diagnosed by a rise in SCr, which
occurs 24 to 72 hours after AKI. In severe cases of AKI, early
renal replacement therapies are recommended to maintain
fluid balance and solute clearance until recovery of renal
function,19,20 but there are no effective drugs that can be
given at the diagnosis of AKI in order to improve recovery,
limit injury, and prevent fibrosis.21
We report here on a model of AKI in rats (unilateral
30 minutes ischemia with contralateral nephrectomy), which
results in a peak rise in SCr within 24 hours. Administration of
IKK16, a specific inhibitor of IKK, at 24 hours inhibited the
activation of NF-jB (peak at 48 hours after AKI), aided the
recovery of renal glomerular (SCr, urea, and eCCL) and tubular
function (fractional excretion of sodium), prevented further
injury (histology), and reduced renal fibrosis (Sirius red
staining) at 28 days. To our knowledge, this is the first report
of an intervention that can be given at peak creatinine to
improve functional recovery and prevent the fibrosis associ-
ated with AKI.
What, then, is the mechanism(s) by which inhibition of IKK
prevents fibrosis? We report here that inhibition of IKK (at
24 hours after AKI) prevents fibrosis, indicating that the
transient activation of IKK early after AKI drives the fibrotic
process in the kidney. We also report that the fibrosis at
28 days after AKI is preceded by a transient rise in tissue
macrophages (CD68+ staining), which was maximal at day 7
after AKI. Similarly, Ysebaert et al (2000) reported a
reversible increase in macrophages, which peaked at 5 days
after AKI.18 Inhibition of IKK abolished the accumulation of
macrophages at day 7 after AKI. In CKD patients, macrophage
numbers closely correlate with glomerular scarring and
interstitial fibrosis.17 AKI results in a shift of macrophage
Figure 7. The effect of late administration of the IjB kinase inhibitor IKK16 (24 hours postreperfusion) on
the expression of transforming growth factor-b (TGF-b) (A), and the expression of both phosphorylated and
total Smad2/3 (B) at 7 days postreperfusion. TGF-b causes downstream Smad2/3 phosphorylation via
binding to type I/II TGF-b receptors. Sham 7 days+vehicle: n=4: ischemia reperfusion injury (IRI)+7 days
vehicle: n=5: IRI+7 days and IKK16 1.0 mg/kg: n=5. Data are presented as meanSEM for the number of
observations. #P<0.05 vs sham, *P<0.05. OD indicates optical density.
Figure 8. The effect of late administration of the IjB kinase
inhibitor IKK16 (24 hours postreperfusion) on the expression of
fibronectin at 28 days postreperfusion. Fibronectin is a compo-
nent of the extracellular matrix. Sham 28 days+vehicle: n=4:
ischemia reperfusion injury (IRI)+28 days vehicle: n=5:
IRI+28 days and IKK16 1.0 mg/kg: n=5. Data are presented as
meanSEM for the number of observations. *P<0.05. OD
indicates optical density.
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polarization in the kidney from M1 (F4/80+ and CD301) to
M2 (F4/80 and CD301+); the latter of which produce high
levels of TGF-b.22 We report here that AKI results in a rise in
TGF-b (at 7 days after AKI), which was abolished in rats
treated with the IKK inhibitor. As TGF-b drives fibrosis, we
speculate that prevention by IKK16 of the formation of TGF-b
importantly contributes to the observed prevention of fibrosis
by IKK inhibition.
How does prevention of TGF-b formation by IKK16 reduce
fibrosis? TGF-b increases the activity of NADPH oxidase,
which, in turn, drives the generation of myofibroblasts within
the kidney.23 When activated with TGF-b, the following cells
can generate myofibroblasts: resident fibroblasts, pericytes,24
endothelial cells,25 epithelial cells,26 and bone marrow–
derived cells.27 We have confirmed with a-smooth muscle
actin staining that myofibroblasts are present 7 days after IRI
in the kidney. We have discovered that inhibition of IKK at
24 hours after IRI abolishes the formation of myofibroblasts
seen in vehicle-treated animals at 7 days after IRI. The finding
that inhibition of IKK attenuates myofibroblast formation and
collagen I production caused by TGF-b in dermal fibroblasts
in vitro28 supports the view that activation of IKK is a key
driver of the phenotypic change caused by TGF-b in fibrob-
lasts and potentially other cells.
The binding of TGF-b to its receptor results in the
phosphorylation and activation of the signaling molecules
Smad2/3, which, in turn, results in the expression of target
genes including the genes of fibronectin and collagen I and III.
We report here that unilateral renal ischemia results in
activation of Smad2/3 (measured as phospho-Smad2/3 by
Western blot analysis) at 7 days after the insult. Like the
formation of TGF-b, the activation of Smad2/3 was abolished
in kidneys of rats treated with IKK16 at 24 hours after IRI.
Interestingly, the formation of TGF-b (which became signifi-
cant at 7 days after the insult) was sustained for 28 days and
associated with the expression of fibronectin and collagen I
and III. Most notably, early inhibition of IKK (with a single
injection of IKK16 at 24 hours after the insult) abolished the
expression of TGF-b, fibronectin, and collagen I and III caused
by IRI within 28 days.
Taken together, these findings support the conclusions
that the administration of IKK at 24 hours after renal ischemia
abolishes both myofibroblast formation and TGF-b formation.
Prevention of the expression of TGF-b by inhibition of IKK
abolishes the TGF-b–dependent activation of Smad2/3 as
well as the expression of the Smad2/3-dependet target genes
fibronectin and collagen I and III. These data indicate that the
activation of IKK is an early and pivotal step in the initiation of
Figure 9. The effect of late administration of the IjB kinase inhibitor IKK16 (days 7–13 post-unilateral ureteral obstruction [UUO]) on collagen
deposition as stained by Sirius red (top row) (scale bar, 250 lm), myofibroblast formation as stained by a-smooth muscle actin (a-SMA) (middle
row) (scale bar, 200 lm), and macrophage accumulation as measured for CD68+ (scale bar, 100 lm). Ten randomly selected fields from each
kidney were selected and analyzed for the determination of percentage stained rat kidney tissue using ImageJ software. Contralateral kidneys
(as control): n=11 (110 total fields); 7 days post-UUO: n=6 (60 total fields); 14 days post-UUO: n=9 (90 total fields); and 14 days post-
UUO+IKK16 1.0 mg/kg: n=10 (100 total fields). Data are presented as meanSEM for the number of observations. *P<0.05 vs vehicle.
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Figure 10. The effect of unilateral ureteral obstruction (UUO) at 7 and 14 days, and the effect of late
administration of the IjB kinase inhibitor IKK16 (1.0 mg/kg SC days 7 to 13 post-UUO) on the nuclear factor-
jB (NF-jB) pathway, fibrotic markers, and extracellular matrix components. Activation of IjBa was measured
as phosphorylation of Ser32/36 on IjBa (A), the activation of IjBa results in the activation of IKK, measured as
the phosphorylation of IKKa/b at Ser176/180 (B), which results in nuclear translocation of the p65 subunit of
NF-jB (shown in C and G). UUO causes a severe tubulointersitial fibrosis, driven by transforming growth
factor-b (TGF-b) (D) and downstream Smad2/3 activation (E), resulting in the overproduction of extracellular
matrix components such as fibronectin (F). (Representative images displayed in G), p65 images 960
magnification (scale bar, 50 lm) and zoom 960 magnification plus92.5 digital zoom (scale bar 40 lm). (A,
B, and C) Contralateral: n=8; 7 days post-UUO: n=3; 14 days post-UUO+10% dimethyl sulfoxide vehicle days
7 to 13: n=6; and 14 days post-UUO+1.0 mg/kg IKK16: n=5. (C, D, and E) Contralateral: n=8; 7 days post-
UUO: n=4; 14 days post-UUO+10% dimethyl sulfoxide vehicle days 7 to 13: n=5; and 14 days post-
UUO+1.0 mg/kg IKK16: n=5. Data are presented as meanSEM for the number of observations. *P<0.05 vs
contralateral (unless otherwise stated). OD indicates optical density.
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renal fibrosis following ischemia-reperfusion. This raises the
question of whether the activation of IKK also plays a pivotal
role in models of renal fibrosis caused by other stimuli. UUO
causes severe inflammation and subsequent fibrosis. In order
to confirm that the activation of IKK is essential in the
pathophysiology of the fibrosis development caused by UUO,
we have treated rats from day 7 to day 13 after ureteral
obstruction. We report that UUO resulted in the sustained
activation of NF-jB (measured as IjBa phosphorylation, IKK
phosphorylation, and nuclear translocation of p65 at day 14
after UUO) as well as a significant renal fibrosis. Administra-
tion of IKK16 abolished the activation of NF-jB and reduced
the fibrosis caused by UUO. Development of fibrosis caused
by UUO was also associated with the formation of TGF-b, the
TGF-b–dependent activation of Smad2/3, and the formation
of fibronectin. All of these events were abolished by IKK16,
confirming in a second model of renal fibrosis that the
formation of TGF-b, the TGF-b–dependent activation of
Smad2/3, and the formation of fibronectin are IKK-dependent
phenomena.
There is evidence that activation of IKK/NF-jB plays a key
role in the development of fibrosis on other organs. Indeed,
the formation of lung fibrosis caused by bleomycin in the
mouse is associated with the activation of NF-jB in fibrob-
lasts,29 and inhibition of IKKb significantly reduced the
pulmonary fibrosis caused by bleomycin.30 In addition,
inhibition of IKK has been shown to limit myofibroblast
formation and fibrosis in a mouse model of nonalcoholic fatty
liver disease.31 Activation of IKK (knock-in model) also results
in cardiac fibrosis and heart failure,32 suggesting that
activation of IKK may play a pivotal role as driver of the
fibrotic process.
Conclusions
The present study demonstrates, for the first time, that the
administration of an IKK inhibitor at a timewhen peak creatinine
levels had already occurred is still able to: (1) improve recovery
of renal glomerular and tubular function, (2) prevent further
injury, and (3) prevent fibrosis at 28 days after the AKI insult.
This study also shows that the activation of IKK is an early and
pivotal step in the development of renal fibrosis caused by
either ischemia-reperfusion (AKI) or ureteral obstruction.
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Table S1. The dose response of IKK16 (at 24 h into reperfusion) in a rat model of 30 min of 
renal ischaemia followed by 48 h of reperfusion (IRI) on markers of renal, glomerular and 
tubular function. 
Serum urea, serum creatinine and estimated creatinine clearance were measured as indicators 
of glomerular dysfunction, and fractional excretion of sodium as indicator of tubular 
dysfunction at 48 h of reperfusion. Sham + Vehicle: n=11, 10 % DMSO (1 ml/kg i.v.) 24 h 
into reperfusion; IRI + Vehicle: n=11, 10 % DMSO (1 ml/kg i.v.)  h into reperfusion; IRI + 
IKK16 0.1 mg/kg: n=5; 0.1 mg/kg IKK-16 (1 ml/kg i.v.) 24 h into reperfusion; IRI + IKK16 
0.3 mg/kg: n=7, 0.3 mg/kg IKK-16 (1 ml/kg i.v.) 24 h into reperfusion; IRI + IKK16 1 
mg/kg: n=9, 1 mg/kg IKK-16 (1 ml/kg i.v.) 24 h into reperfusion. All animals culled at 48 h 
post reperfusion. Data are presented as mean ± SEM of n observations, ★P<0.05 vs IRI + 
Vehicle. 
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Figure S1. The effect of the late administration of IKK16 (24 h post reperfusion) on 
serum KIM-1. 
 
Sham + vehicle: n=5; 2 day post reperfusion: n=5; 7 days post reperfusion: n=5; 28 days 
post reperfusion: n=5; 1mg/kg IKK16 24 h post reperfusion + 2 day reperfusion: n=5; 
1mg/kg IKK16 24 h post reperfusion + 7 day reperfusion: n=5; 1mg/kg IKK16 24 h post 
reperfusion + 28 day reperfusion: n=5. Data are presented as mean ± SEM of n 
observations, ★P<0.05 vs. Sham. 
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